Table 1 Demographics and baseline characteristics

From: Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

 

East Asian patientsa

Japanese patients

 

DRd (n = 52)

Rd (n = 44)

DRd (n = 21)

Rd (n = 15)

Median (range) age, years

64 (34–80)

65 (44–85)

68 (45–80)

67 (50–81)

 <65, n (%)

28 (53.8)

21 (47.7)

6 (28.6)

4 (26.7)

 65–74, n (%)

18 (34.6)

19 (43.2)

12 (57.1)

9 (60.0)

 ≥75, n (%)

6 (11.5)

4 (9.1)

3 (14.3)

2 (13.3)

Female/male sex, %

50.0/50.0

38.6/61.4

47.6/52.4

40.0/60.0

ECOG score, n (%)

0

25 (48.1)

21 (47.7)

14 (66.7)

10 (66.7)

1

25 (48.1)

22 (50.0)

7 (33.3)

4 (26.7)

2

2 (3.8)

1 (2.3)

0 (0.0)

1 (6.7)

Risk stratificationb, n

50

42

20

15

 Standard risk, n (%)

46 (92.0)

35 (83.3)

17 (85.0)

10 (66.7)

 High risk, n (%)

4 (8.0)

7 (16.7)

3 (15.0)

5 (33.3)

  del(17p)

3 (6.0)

3 (7.1)

3 (15.0)

3 (20.0)

  t(4;14)

1 (2.0)

6 (14.3)

0 (0.0)

4 (26.7)

  t(14;16)

0 (0.0)

1 (2.4)

0 (0.0)

1 (6.7)

Isotype, n (%)

IgG

31 (59.6)

23 (52.3)

16 (76.2)

8 (53.3)

IgA

9 (17.3)

13 (29.5)

0 (0.0)

4 (26.7)

IgM

1 (1.9)

0 (0.0)

1 (4.8)

0 (0.0)

IgD

2 (3.8)

2 (4.5)

0 (0.0)

1 (6.7)

IgE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Light chain

7 (13.5)

5 (11.4)

3 (14.3)

1 (6.7)

 Kappa

4 (7.7)

3 (6.8)

1 (4.8)

1 (6.7)

 Lambda

3 (5.8)

2 (4.5)

2 (9.5)

0 (0.0)

Biclonal

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Negative immunofixation

2 (3.8)

1 (2.3)

1 (4.8)

1 (6.7)

Median (range) time since diagnosis, years

3.9 (0.8–27.0)

2.6 (0.9–13.5)

3.4 (0.9–27.0)

3.0 (0.9–13.5)

Median (range) number of prior lines

2.0 (1–6)

1.5 (1–6)

1.0 (1–6)

1.0 (1–6)

1 prior line, n (%)

25 (48.1)

22 (50.0)

13 (61.9)

8 (53.3)

2 prior lines, n (%)

17 (32.7)

11 (25.0)

2 (9.5)

6 (40.0)

3 prior lines, n (%)

6 (11.5)

8 (18.2)

3 (14.3)

0 (0.0)

>3 prior lines, n (%)

4 (7.7)

3 (6.8)

3 (14.3)

1 (6.7)

Prior ASCT, n (%)

36 (69.2)

24 (54.5)

12 (57.1)

6 (40.0)

Prior PI, n (%)

43 (82.7)

33 (75.0)

17 (81.0)

13 (86.7)

 Bortezomib

43 (82.7)

33 (75.0)

17 (81.0)

13 (86.7)

 Carfilzomib

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Ixazomib

0 (0.0)

1 (2.3)

0 (0.0)

1 (6.7)

Prior IMiD, n (%)

28 (53.8)

29 (65.9)

7 (33.3)

9 (60.0)

 Lenalidomide

3 (5.8)

2 (4.5)

3 (14.3)

2 (13.3)

 Pomalidomide

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Thalidomide

28 (53.8)

28 (63.6)

7 (33.3)

8 (53.3)

Prior corticosteroid, n (%)

52 (100.0)

44 (100.0)

21 (100.0)

15 (100.0)

Dexamethasone

46 (88.5)

37 (84.1)

16 (76.2)

13 (86.7)

Prednisone

19 (36.5)

18 (40.9)

8 (38.1)

7 (46.7)

Prior alkylating agent, n (%)

50 (96.2)

39 (88.6)

19 (90.5)

14 (93.3)

Prior PI+IMiD, n (%)

22 (42.3)

20 (45.5)

5 (23.8)

7 (46.7)

Refractory to, n (%)

Last line of therapy

19 (36.5)

24 (54.5)

8 (38.1)

8 (53.3)

Bortezomib

14 (26.9)

16 (36.4)

7 (33.3)

7 (46.7)

  1. DRd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ECOG Eastern Cooperative Oncology Group, Ig immunoglobulin, ASCT autologous stem cell transplantation, PI proteasome inhibitor, IMiD immunomodulatory drug
  2. aPatients from Japan, Korea, and Taiwan
  3. bCytogenetic abnormalities were identified by FISH or karyotype testing. Percentages were calculated with the number of subjects in each treatment group as the denominator
Back to article page